The antitumor efficacy of EBV-induced molecule 1 ligand CC chemokine (ELC/CCL19) was evaluated in a murine lung cancer model. The ability of ELC/CCL19 to chemoattract both dendritic cells and T lymphocytes formed the rationale for this study. 
IFN-␥ was performed using a kit from BD PharMingen. For flow cytometry analyses, PE-conjugated Abs (CD3, CD8, CD25) or FITC-conjugated Abs (CD4 and CD11c) were obtained from BD PharMingen. CXCR3 was detected by rabbit-anti-CXCR3 (Zymed Laboratories, San Francisco, CA) and FITC-conjugated polyclonal anti-rabbit IgG (BD PharMingen). Polyclonal goat anti-murine MIG/CXCL9 and anti-murine IP-10/CXCL10 specific anti-serum were produced and characterized as previously described (14) . Anti-mouse IFN-␥ monoclonal (R4-462, American Type Culture Collection, Manassas, VA) neutralizing Ab was purified by affinity chromatography from scid mice ascites, which was generated 3-4 wk after i.p. injection of 10 6 R4-462 hybridoma cells per mouse (15) .
Cell culture
Murine Line 1 alveolar lung tumor (L1C2) and WEHI cell lines were obtained from American Type Culture Collection. The cells were routinely cultured as monolayers in 75 cm 3 tissue culture flasks containing RPMI 1640 (Irvine) supplemented with 10% FBS (Gemini Bio-products, Calabasas, CA), penicillin (100 U/ml), streptomycin (0.1 mg/ml), 2 mM glutamine (JRH Biosciences, Lenexa, KS) and maintained at 37°C in a humidified atmosphere containing 5% CO 2 in air. The cell lines were Mycoplasma free, and cells were used up to the tenth passage before thawing frozen stock cells from liquid N 2 .
Tumorigenesis experiments
A total of 1.5 ϫ 10 5 L1C2 tumor cells were injected s.c. in the right suprascapular area of BALB/c mice and tumor volume was monitored three times per week. Two bisecting diameters of each tumor were measured with calipers. The volume was calculated using the formula V ϭ 0.4ab (2) , where a is the larger diameter and b is the smaller diameter. Five-day-old established tumors were treated with intratumoral injection of 0.5 g of murine recombinant ELC/CCL19 or diluent administered three times a week for 2 wk. For the evaluation of ELC/CCL19 mediated systemic antitumor responses, L1C2 cells were inoculated subcutaneously in the right flank (1.5 ϫ 10 5 cells) and left flank (2 ϫ 10 4 cells). All treatments were administered intratumorally (0.5 g) into the right flank three times a week.
In vivo cytokine neutralization
For in vivo neutralization experiments, 1.5 ϫ 10 5 L1C2 tumor cells were inoculated by s.c. injection in the right suprascapular area of BALB/c mice. Five day established tumors were treated with an intratumoral injection of 0.5 g of recombinant murine ELC/CCL19 or murine serum albumin (used as an irrelevant protein control for injections) and were administered three times per week for 2 wk. Twenty four hours before ELC/CCL19 treatment, and then three times a week, mice were injected i.p. with 1 ml/dose of anti-IP-10/CXCL10, or anti-MIG/CXCL9, or 100 g/dose of purified monoclonal anti-IFN-␥ or appropriate control Abs (goat IgG and rat IgG) at equivalent doses for the duration of the experiment. In response to these Abs, there was a significant reduction of the respective cytokines in vivo (see Fig. 6B ). Tumor volumes were assessed three times per week. Cytokine profiles and splenocyte IFN-␥ ELISPOT were performed 14 days after treatment.
Lymphocyte transfer
A total of 1.5 ϫ 10 5 L1C2 tumor cells were inoculated by s.c. injection in the right suprascapular area of BALB/c mice. Five day established tumors were treated four times with intratumoral injection of 0.5 g of recombinant murine ELC/CCL19 or murine serum albumin. For adoptive transfer experiments, T lymphocytes were isolated from spleens of ELC/CCL19 or diluent-treated tumor-bearing mice by Miltenyi Biotec beads (Auburn, CA) using the manufacturer's protocol and transferred (3.5 ϫ 10 7 ) to naive mice 24 h before L1C2 tumor inoculation (1.5 ϫ 10 5 ) and again 1 wk following tumor inoculation. Tumor volumes were assessed three times per week.
Flow cytometry
On day 12 post tumor inoculation, flow cytometric analyses of tumor nodules for T cell and DC markers were performed with a FACScan cytometer (BD Biosciences, San Jose, CA) in the University of California, Los Angeles, Jonsson Cancer Center Flow Cytometry Core Facility (Los Angeles, CA). Non-necrotic tumors were harvested, cut into small pieces in RPMI 1640, and passed through a sieve (Bellco Glass, Vineland, NJ). Tumor leukocytes were isolated by digesting tumor tissue in collagenase IV (Sigma-Aldrich) in RPMI 1640 for 30 min with stirring at 37 o C. A 10-ml syringe with a blunt-ended 16-gauge needle was used to break down the tissue further. The cell suspension was strained through a disposable plastic strainer (Fisher, Pittsburg, PA) to separate free lymphocytes from tissue matrix. The cells were pelleted at 2,000 rpm for 10 min and cell pellets washed twice to remove collagenase. Leukocytes were further purified using a discontinuous Percoll (Sigma-Aldrich) gradient, collecting at the 35-60% interface following centrifugation at 1,500 rpm for 20 min at 4 o C without brake. The collected cells were washed twice in PBS and stained for flow cytometric evaluation. Because we have Percoll-purified, the percentage of leukocytes in the cell population is approximately Ͼ95%. Cells were identified as lymphocytes or DCs by gating based on forward and side scatter profiles. CD11c ϩ DCs were defined as the bright populations within tumor nodules. A total of 10,000-gated events were collected and analyzed using CellQuest software BD Biosciences). For staining, two or three fluorochromes (PE, FITC, PerCP) were used to gate on the CD3, CD4, and CD8 T lymphocyte population or CD11c ϩ DC in single cell suspensions from tumor nodule. For CXCR3 expression, T cells were doubly stained for CD3 and CXCR3 cell surface markers.
Cytokine determination from tumor nodules
The cytokine profiles in tumors were determined in both ELC/CCL19 and diluent-treated mice as previously described (6) . On day 12 post-tumor inoculation non-necrotic tumors were harvested, cut into small pieces, homogenized, and passed through a sieve (Bellco Glass). Tumor nodule homogenates were evaluated for the production of IL-10, IL-12, GM-CSF, IFN-␥, TGF␤, monokine induced by IFN-␥ (MIG/CXCL9), and IP-10/ CXCL10 by ELISA and PGE 2 by enzyme immunoassay (EIA) and results are expressed as picograms per milligram of total protein. Tumor-derived cytokine and PGE 2 concentrations were corrected for total protein by Bradford assay (Sigma-Aldrich).
Cytokine ELISA
Cytokine protein concentrations from tumor nodules were determined by ELISA as previously described (16) . The plates were read at 490 nm with a Micro Plate (Amersham Biosciences, Sunnyvale, CA). MIG/CXCL9 and IP-10/CXCL10 were quantified by a modification of a double ligand method as previously described (17) . The TGF-␤ ELISA measured TGF-␤1. The sensitivities of the IL-10, GM-CSF, IFN-␥, TGF␤, MIG/CXCL9, and IP-10/CXCL10 ELISAs were 15 pg/ml. The sensitivity for IL-12 was 5 pg/ml.
PGE 2 EIA
PGE 2 concentrations were determined using a kit from Cayman Chemicals (Ann Arbor, MI) according to the manufacturer's instructions as previously described (5) . An Amersham Biosciences Micro Plate Reader read the EIA plates.
ELISPOT
To evaluate the specificity of the ELC/CCL19 treatment, IFN-␥ ELISPOT assay was performed to determine the frequency of splenocyte producing IFN-␥ in response to irradiated specific tumors. On day 14 post-tumor inoculation, spleens from ELC/CCL19 or diluent control treated mice were harvested, crushed, RBC depleted, filtered through a 10 m filter (Millipore, Minneapolis, MN), and coincubated with either irradiated specific L1C2 cell line or the non-specific syngeneic WEHI cell line at a ratio of 10 lymphocyte effectors:1 stimulator for 24 h. A single cell suspension of L1C2 or WEHI tumor cells (10 6 cells/ml) was irradiated with 80 Gy of gamma irradiation in a 137 Cs gamma irradiator. Spots were quantified with an Immunospot Image Analyzer (Cellular Technologies, Cleveland, OH) at the University of California, Los Angeles Immunology Core Facility (Los Angeles, CA).
Histology
On day 12 post-tumor inoculation, non-necrotic tumors were isolated, placed in 10% formalin, and embedded in paraffin. Sections (5 m) were prepared for H&E staining and histopathological examination.
Statistical analyses
Groups of 6 -8 mice were used in each experiment. Statistical analyses of the data were performed using the unpaired two-tailed Student's t test for all significant data presented in the manuscript.
Results

ELC/CCL19 mediates potent systemic antitumor responses in vivo
The antitumor efficacy of ELC/CCL19 was evaluated in BALB/c mice with established L1C2 tumors. Intratumoral administration of ELC/CCL19 (0.5 g) three times per week caused a significant reduction in tumor volumes compared with diluent-treated tumorbearing control mice ( vs ELC/CCL19 treated tumor-bearing mice showed an approximate 3-fold overall decrease in the tumor growth rate on both the treatment as well as the contralateral side during ELC/CCL19 treatment.
ELC/CCL19 enhances frequency of T cell subsets and DC at the tumor site
H&E staining of tumors showed an enhanced mononuclear infiltration following intratumoral ELC/CCL19 therapy compared with control ( Fig. 3A) . Because ELC/CCL19 is chemotactic for both T cells and DCs, we hypothesized that intratumoral injections of ELC/CCL19 would elicit migration of these cell types to the tumor site. Flow cytometric evaluation of single cell suspensions of tumor nodules showed that compared to diluent treated controls ELC/CCL19 administration led to an increase in the frequency of CD4 ϩ (66%), CD8 ϩ (57%), and CD3 ϩ CXCR3 ϩ (50%) T cells as well as the DCs expressing CD11c ϩ (40%) infiltrating the tumors (Fig. 3B) .
ELC/CCL19 therapy promotes type-1 cytokine and chemokine release as well as a decline in the immunosuppressive molecules TGF␤ and PGE 2
On the basis of previous reports indicating that tumor progression can be modified by host cytokine profiles (18, 19) , we evaluated the cytokine production from tumor sites. Cytokine profiles at the tumor sites of BALB/c mice treated with ELC/CCL19 were quantified. Compared with diluent-treated controls, the tumor sites of ELC/CCL19 treated mice had enhanced elaboration of IFN-␥ (5-fold), MIG/CXCL9 (5-fold), IP-10/CXCL10 (5-fold), GM-CSF(4-fold), and IL-12 (5-fold), but a decrease in the immunosuppressive molecules TGF␤ (2-fold) and PGE 2 (2-fold) (Fig. 4, A and B, p Ͻ 0.05).
ELC/CCL19 therapy induces specific T cell responses
To evaluate the specificity of the ELC/CCL19 treatment, IFN-␥ ELISPOT assay was performed on splenocytes from ELC/CCL19 There were minimal responses to the control syngeneic tumor WEHI (Fig. 5) . mononuclear infiltration, 2. tumor) . B, ELC/CCL19 enhances influx of T cell subsets and DCs at the tumor site. Five-day-old established tumors were treated with intratumoral injection of 0.5 g of murine recombinant ELC/CCL19 every other day for four days before tumors were harvested for flow cytometric analysis. Single cell suspensions of non-necrotic tumor nodules were prepared from ELC/CCL19 and diluent-treated mice. Cell surface staining or T cell markers CD4, CD8, and the chemokine receptor CXCR3 as well as the DC marker CD11c were evaluated by flow cytometry. Cells were identified as lymphocytes or DC by gating on the forward and side scatter profiles; 10,000 gated events were collected and analyzed using CellQuest software. Within the gated T lymphocyte population, intratumoral injection of ELC/CCL19 led to an increase in the frequency of CD4 ϩ , CD8 ϩ , and CXCR3 ϩ events compared with the diluent control ‫,ء(‬ p Ͻ 0.001). Within the gated DC population, intratumoral injection of ELC/CCL19 led to an increase in the frequency of CD11c ϩ events compared with the diluent control ‫,ء(‬ p Ͻ 0.001) (n ϭ 8 mice/group).
ELC/CCL19 mediated antitumor responses require IFN-␥, MIG/ CCL9 and IP-10/CCL10
To determine the importance of MIG/CXCL9, IP-10/CXCL10, and IFN-␥ in the ELC/CCL19 mediated antitumor response, these cytokines were depleted in ELC/CCL19 treated mice. Anti-IP-10/ CXCL10 and anti-MIG/CXCL9 each partially yet significantly inhibited whereas anti-IFN-␥ completely inhibited the antitumor efficacy of ELC/CCL19 (Fig. 6A , ‫,ء‬ p Ͻ 0.01 compared with the control Ab group). Neutralization of IFN-␥ caused a significant decrease in both MIG/CXCL9 and IP-10/CXCL10 consistent with previous studies indicating that these chemokines are largely IFN-␥ dependent (20) . Thus, an increase in IFN-␥ at the tumor site of ELC/CCL19 treated mice could explain the relative increases in IP-10/CXCL10 and MIG/CXCL9. The converse was also observed; IFN-␥ production at the tumor site was found to be MIG/ CXCL9-and IP-10/CXCL10-dependent as indicated by the fact that neutralization of these cytokines caused a significant decrease in IFN-␥ (Fig. 6B) . Neutralization of any one of these cytokines caused a concomitant decrease in all three cytokines, thus indicating that IFN-␥, MIG/CXCL9, and IP-10/CXCL10 are interdependent in the ELC/CCL19 mediated antitumor responses. In addition, neutralization of any one of these cytokines in vivo led to a decrease in the frequency of tumor specific T cells producing IFN-␥ (Fig. 6C) .
T lymphocytes from ELC/CCL19 treated mice transfer the antitumor therapeutic efficacy to naive mice
To determine whether the therapeutic efficacy of ELC/CCL19 could be transferred, 3.5 ϫ 10 7 T cells from ELC/CCL19 treated tumor bearing mice were administered to naive mice one day before and 1 wk following tumor challenge. Transfer of T lymphocytes from ELC/CCL19 treated tumor-bearing mice conferred the therapeutic efficacy of ELC/CCL19 to naive mice challenged with tumors and caused a significant reduction in tumor growth rate compared with control transfer (Fig. 7) .
Discussion
Host APCs are critical for the cross-presentation of tumor Ags (1). However, tumors have the capacity to limit APC maturation, function, and infiltration of the tumor site (3, (21) (22) (23) . Thus molecules that attract host APCs and T cells could serve as potent agents for cancer immunotherapy. We have previously shown that intratumoral injection of recombinant SLC/CCL21 mediated a T cell dependent antitumor response in vivo (8) . Because both SLC/CCL21 and ELC/CCL19 mediate their effects through the specific G protein-coupled seven-transmembrane domain chemokine receptor CCR 7 (13) and are important for colocalization of DCs and T cells for the T cell immune response (24), we determined the antitumor efficacy of recombinant ELC/CCL19 and the effector molecules important for mediating these responses.
ELC/CCL19 produced by a subset of DCs, and possibly by other non-lymphoid cells, in T cell areas of lymphoid tissue (25) strongly attracts naive T cells and DCs (9 -12). Because DCs are potent APCs that function as principal activators of T cells (24) , the capacity of ELC/CCL19 to facilitate the colocalization of both DC and T cells may reverse tumor-mediated immune suppression and orchestrate effective cell-mediated immune responses. The expression of ELC/CCL19 in a breast cancer cell line mediated rejection of the transduced tumor through a mechanism involving NK and CD4 ϩ cells (26) . Recent studies have shown that ELC/ CCL19 released from polymer rods entrapped migratory Langerhans cells. The Langerhans cells, when loaded with tumor-associated Ags in situ, led to potent CTL activities and protective antitumor immunity (27) . Nomura et al. (28) showed an enhancement of anti-tumor immunity by tumor cells transfected with ELC/ CCL19 and stromal cell-derived factor-1␣ chemokine genes.
Based on these properties, we speculated that ELC/CCL19 would be an important protein for evaluation in cancer immunotherapy.
The antitumor activity of ELC/CCL19 was determined in a transplantable model for lung cancer by injecting recombinant ELC/CCL19 intratumorally. The efficacy of injecting immune stimulators intratumorally for the treatment of cancer has been demonstrated in recent studies; intratumoral injection of recombinant SLC/CCL21 evidenced potent antitumor responses in murine lung cancer models (8, 29) . In experimental models, DC injection into tumor masses has antitumor activity against micro metastases. However, if ex vivo generated DCs are genetically modified to express IL-12 (30, 31), IL-7 (7), CD40L (32), or IL-2 (33), they are highly efficacious against malignant tumors and elicit specific CTLs. Our rationale for injecting ELC/CCL19 intratumorally was to colocalize DCs and T cells at the source of tumor Ags where they can prime specific antitumor immune responses. This approach harnesses DCs to initiate antitumor immunity by using chemokine to attract endogenous DCs to tumors. Thus this strategy circumvents the ex vivo manipulation of DCs and tumor cells or tumor Ags. In many clinical situations access to intratumoral injection is achievable. The induction of an Ag-specific response requires the activation of naïve T lymphocytes by APCs bearing cognate Ag. T cell priming is thought to occur only in specialized compartments (i.e., secondary lymphoid organs such as the spleen and LNs). However, recent work by Kirk et al. (34) has shown that intratumoral administration of SLC gene-modified DCs are readily infiltrated by host-derived T cells and these T cells were primed within the tumor mass as measured by expression of activation markers and the cytokine IFN-␥. In addition, the data suggested that T cell priming and the generation of functional antitumor effector cells could occur in the absence of functional lymph nodes. Our results in this study show that this approach is effective in generating systemic antitumor responses. ELC/CCL19 injected intratumorally evidenced potent systemic antitumor responses. The reduced tumor burden in ELC/CCL19 treated mice was accompanied by extensive lymphocyte as well as DC infiltrates of the tumor sites.
The cytokine production at the tumor site was altered as a result of ELC/CCL19 therapy. The following cytokines were measured: PGE 2 , TGF␤, IFN-␥, GM-CSF, IL-12, MIG/CXCL9, and IP-10/ CXCL10. These cytokines were evaluated for the following reasons: the tumor site has been documented to be an abundant source of PGE 2 and TGF␤ that have been shown to suppress immune responses (5, 35) and to promote angiogenesis (36, 37) . Abs to TGF␤ and PGE 2 suppress tumor growth in in vivo model systems (38, 39) . TGF␤ is known to suppress Ag presentation, antagonize CTL generation, and macrophage activation (35) . ELC/CCL19-treated tumor-bearing mice showed significant reductions in PGE 2 and TGF␤ at the tumor sites. Thus possible benefits of an ELC/ CCL19-mediated decrease in these molecules include promotion of Ag presentation and CTL generation (35) , as well as a limitation of angiogenesis (36, 37) .
Apart from a decrease in TGF␤ and PGE 2 , the tumor sites of ELC/CCL19 treated mice revealed significant increases in IFN-␥, IL-12, IP-10/CXCL10, MIG/CXCL9, and GM-CSF. It is well documented that successful immunotherapy shifts tumor-specific T cell responses to a type-1 cytokine profile (40) . Both IL-12 and IFN-␥ mediate a range of biological effects that facilitate anticancer immunity. IL-12, a cytokine produced by macrophages (41) and DC (42) , mediates potent antitumor effects that are the result of several actions involving the induction of CTL (43), Th1-mediated immune responses, and NK activation (41) , as well as the impairment of tumor vascularization (44) . An increase in GM-CSF in ELC/CCL19-treated mice could enhance DC maturation and Ag presentation (24) . IP-10/CXCL10 and MIG/CXCL9 are CXC chemokines that chemoattract activated T cells expressing the CXCR3 chemokine receptor (45) and are known to have potent antitumor and antiangiogenic properties (46 -49) . MIG/CXCL9 and IP-10/ CXCL10 are potent angiostatic factors that are induced by IFN-␥ (48, 50, 51) . The tumor reductions observed in this model might be due to T cell-dependent immunity, as well as participation by T cells secreting IFN-␥ in inhibiting angiogenesis (51) by inducing MIG/CCL9 and IP-10/CCL10. Hence, an increase in IFN-␥ at the tumor site of ELC/CCL19 treated mice could explain the relative increases in IP-10/CXCL10 and MIG/CCL9. Both MIG/CCL9 and IP-10/CCL10 are chemotactic for stimulated CXCR3-expressing T lymphocytes that could further amplify IFN-␥ at the tumor site (52) . Flow cytometric determinations revealed that both CD4 and CD8 cells as well as CD3 ϩ T cells expressing CXCR3 were increased at the in ELC/CCL19 treated mice. Braun et al. (26) had shown that ELC/CCL19 in a breast cancer cell line mediated rejection of the transduced tumor through a mechanism involving NK and CD4 ϩ cells. Future experiments will address the contribution of NK cells in intratumoral ELC mediated anti-tumor responses.
To determine the importance of MIG/CXL9, IP-10/CXCL10, and IFN-␥ in the ELC/CCL19 mediated antitumor response, these cytokines were depleted in ELC/CCL19 treated mice. Anti-MIG/ CXL9 or IP-10/CXL10 each partially yet significantly inhibited the antitumor response. Because MIG/CCL9 and IP-10/CCL10 share the same receptor (CXCR3), one possible explanation of a partial inhibition in tumor growth is that neutralization of one ligand may overexpose the receptor to the other ligand. An alternative explanation is that residual cytokines such as IFN-␥ inducible T cell ␣ chemoattractant (ITAC/CXCL11) present after in vivo neutralization of MIG/CXL9 and IP-10/CCL10 play interrelated roles in the recruitment of CXCR3 activated T cells in ELC/ CCL19 mediated antitumor responses. In vivo depletion of IFN-␥ completely inhibited the antitumor efficacy of ELC/CCL19. The fact that neutralization of IFN-␥ was the most efficient at inhibiting ELC/CCL19 mediated antitumor response may be due to a decrease in the IFN-␥ dependent CXCR3 ligands MIG/CXL9 and IP-10/CXCL10 indicating that these chemokines are largely IFN-␥ dependent. One interesting question is whether IFN-␥, and therefore, presumably MIG and IP-10, are necessary in the afferent, efferent, or both phases of the immune response. This question could be addressed in future adoptive transfer experiments in which these cytokines are neutralized after transfer of lymphocytes from CCL19-treated tumor-bearing mice, i.e., is anti-IFN-␥ treatment as effective at reversing the antitumor efficacy of CCL19 when administered after the establishment of a specific T cell response (is it necessary for the cytotoxic activity of elicited T cells, or in their recruitment to the tumor site?). CXCL9 (MIG) and CXCL10 (IP-10), although ligands of the CXCR3 receptor, do not appear to play redundant roles in the anti-tumor effect of CCL19 because inhibition of a single ligand significantly, though less effectively than anti-IFN-␥ treatment, reduced tumor growth. The increase in type-1 cytokines may in part be due to an increase in specificity against the autologous tumor; splenocytes from ELC/ CCL19 treated mice had a significantly increased frequency of tumor specific T cells producing IFN-␥. In addition, transfer of T lymphocytes from ELC/CCL19 treated tumor bearing mice transferred the antitumor therapeutic efficacy to naive mice.
The current study indicates that ELC/CCL19 administered intratumorally leads to the generation of tumor specific antitumor responses that are dependent on IFN-␥. The potent antitumor properties demonstrated in this model provide a strong rationale for further evaluation of ELC/CCL19 regulation of tumor immunity and its use in immunotherapy for lung cancer.
